import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "best-peptides-weight-loss-research-glp1-aod9604-semaglutide",
  title: "Best Peptides for Weight Loss Research: GLP-1s, AOD-9604, and Beyond",
  description:
    "A research-focused comparison of peptides studied in the context of fat metabolism and body composition — covering semaglutide, tirzepatide, retatrutide, AOD-9604, and MOTS-c, with summaries of key preclinical and clinical evidence.",
  category: "Compound Profiles",
  readMinutes: 10,
  publishedAt: "2026-06-04",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Few areas in peptide research have attracted more scientific attention in the past decade than metabolic regulation and fat mass reduction. Driven by the GLP-1 revolution and a growing understanding of adipose biology, researchers now have access to a sophisticated toolkit of compounds that act through distinct mechanisms to modulate body composition. This article provides a mechanistic overview of the peptides most studied in weight-related research contexts, organized by their primary mechanism of action.",
    },
    {
      type: "heading",
      text: "The GLP-1 Axis: The Foundation of Modern Metabolic Research",
    },
    {
      type: "paragraph",
      text: "Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from L-cells in the intestinal mucosa in response to nutrient ingestion. It acts on the pancreas to stimulate insulin secretion, suppresses glucagon, slows gastric emptying, and — critically for weight research — acts on hypothalamic neurons to reduce appetite and caloric intake. The GLP-1 receptor (GLP-1R) is expressed in the arcuate and paraventricular nuclei of the hypothalamus, the brainstem, and peripheral tissues.",
    },
    {
      type: "heading",
      text: "1. Semaglutide — GLP-1 Receptor Agonist",
    },
    {
      type: "paragraph",
      text: "Semaglutide is a fatty acid-modified GLP-1 analog with 94% sequence homology to native GLP-1 and an extended half-life of approximately 165–184 hours due to albumin binding. In the STEP trial series, weekly subcutaneous semaglutide 2.4 mg produced mean body weight reductions of 14.9–17.4% over 68 weeks in obese non-diabetic subjects. CNS mechanisms play a central role: semaglutide reduces activity in brain regions associated with food reward and craving while increasing signaling in satiety pathways. For researchers, semaglutide is one of the most thoroughly characterized compounds in metabolic peptide research.",
    },
    {
      type: "heading",
      text: "2. Tirzepatide — Dual GLP-1/GIP Agonist",
    },
    {
      type: "paragraph",
      text: "Tirzepatide is a first-in-class twincretin peptide that co-agonizes both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. The SURMOUNT-1 trial demonstrated mean weight reductions of up to 22.5% at the 15 mg dose over 72 weeks — surpassing semaglutide in head-to-head comparisons. The GIP component contributes to improved insulin sensitivity, lipid metabolism, and reduced nausea compared to GLP-1-only agonists. Researchers studying tirzepatide should account for its dual receptor pharmacology when designing assays.",
    },
    {
      type: "heading",
      text: "3. Retatrutide — Triple GLP-1/GIP/Glucagon Agonist",
    },
    {
      type: "paragraph",
      text: "Retatrutide adds glucagon receptor agonism to the dual incretin profile of tirzepatide, creating a triple agonist. Glucagon receptor activation increases energy expenditure and hepatic fat oxidation — effects that GLP-1 alone does not produce. Phase 2 data published in the New England Journal of Medicine (2023) showed mean weight reductions of 24.2% at 48 weeks with the 12 mg dose. Retatrutide represents the current frontier of mechanistic weight-loss peptide research, and its full receptor pharmacodynamics are still being characterized.",
    },
    {
      type: "heading",
      text: "4. AOD-9604 — Lipolytic GH Fragment",
    },
    {
      type: "paragraph",
      text: "AOD-9604 is a synthetic fragment of the C-terminal end of growth hormone (hGH 177–191) that retains GH's lipolytic activity without the growth-promoting or diabetogenic effects of full-length GH. It acts by stimulating lipolysis in adipose tissue and inhibiting lipogenesis, with demonstrated efficacy in obese animal models. In clinical trials, AOD-9604 showed a favorable safety profile through Phase II, though Phase III trials did not meet primary endpoints. It remains an active area of preclinical research, particularly for its mechanism of directly targeting adipose tissue metabolism without IGF-1 axis involvement.",
    },
    {
      type: "heading",
      text: "5. MOTS-c — Mitochondrial-Derived Metabolic Regulator",
    },
    {
      type: "paragraph",
      text: "MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a short peptide encoded in mitochondrial DNA that plays a role in metabolic homeostasis. Research in rodent models has shown that MOTS-c administration reduces adiposity, improves insulin sensitivity, and increases physical performance — effects linked to AMPK activation and improved mitochondrial function. Unlike GLP-1-axis peptides, MOTS-c acts at the cellular energy level, making it mechanistically distinct and of interest for longevity and metabolic aging research.",
    },
    {
      type: "heading",
      text: "6. Adipotide (FTPP) — Experimental Adipose-Targeted Apoptosis",
    },
    {
      type: "paragraph",
      text: "Adipotide is a pro-apoptotic chimeric peptide that selectively targets the vasculature supplying white adipose tissue, inducing apoptosis in fat-specific blood vessels and causing adipocyte death by ischemia. Preclinical studies in obese monkeys (Macaca mulatta) produced dramatic and rapid fat loss without changes in diet. The mechanism is entirely unlike GLP-1 agonism — it physically ablates adipose vasculature. Due to kidney toxicity at higher doses in primate studies, clinical development has been cautious. It remains one of the more unusual and mechanistically extreme compounds in the metabolic peptide landscape.",
    },
    {
      type: "heading",
      text: "Comparative Overview",
    },
    {
      type: "table",
      headers: ["Peptide", "Mechanism", "Evidence Stage", "Key Distinguishing Feature"],
      rows: [
        ["Semaglutide", "GLP-1R agonist", "Phase 3 / Approved", "CNS appetite suppression; longest half-life in class"],
        ["Tirzepatide", "GLP-1R + GIPR dual agonist", "Phase 3 / Approved", "Superior weight loss vs. semaglutide; improved lipid profile"],
        ["Retatrutide", "GLP-1R + GIPR + GCGR triple agonist", "Phase 2", "Highest weight loss in published data; adds energy expenditure via GCGR"],
        ["AOD-9604", "GH lipolytic fragment", "Phase 2 (discontinued)", "Direct fat-selective lipolysis; no IGF-1 axis involvement"],
        ["MOTS-c", "Mitochondrial AMPK activator", "Preclinical", "Cellular energy mechanism; aging/metabolic research angle"],
        ["Adipotide (FTPP)", "Adipose vasculature apoptosis", "Preclinical (primate)", "Extreme mechanism; renal safety concern limits translation"],
      ],
    },
    {
      type: "heading",
      text: "Research Design Considerations",
    },
    {
      type: "list",
      items: [
        "GLP-1 agonist studies should include endpoints for lean mass preservation — significant fat loss can be accompanied by muscle catabolism, an important variable to track",
        "When comparing GLP-1 to GIP/GCGR co-agonists, separate receptor pharmacology assays are needed to attribute effects accurately",
        "AOD-9604 studies should distinguish lipolysis (fatty acid release) from fat oxidation — the compound affects the former more reliably than the latter",
        "MOTS-c experiments require careful mitochondrial function endpoints (oxygen consumption rate, AMPK phosphorylation) to capture its primary mechanism",
        "All metabolic peptide studies benefit from comprehensive body composition endpoints: fat mass, lean mass, and visceral adiposity measured separately",
      ],
    },
    {
      type: "heading",
      text: "Conclusion",
    },
    {
      type: "paragraph",
      text: "The peptide research toolkit for metabolic and body composition studies has never been richer. GLP-1 agonists dominate by volume of published evidence, but compounds like AOD-9604, MOTS-c, and the emerging triple agonists offer mechanistically distinct approaches that remain scientifically underexplored. Researchers choosing a compound for a specific study should align mechanism of action with study endpoints, rather than defaulting to the most well-known compound. The most interesting discoveries in this field will likely come from mechanistic comparison work rather than efficacy replication.",
    },
    {
      type: "divider",
    },
    {
      type: "disclaimer",
      text: "This article is intended for educational and research purposes only. All compounds discussed are sold by Nexphoria for laboratory and in vitro research use only. They are not intended for human or veterinary administration, and this article does not constitute medical advice.",
    },
  ],
};
